CHEK2 has also been linked to an increased risk of contralateral BC and, in some studies, CRC, and prostate cancer, while ATM mutations may confer a slightly increased risk of pancreatic and possibly OC [11,12,13]. This evidence concerns the gene CHEK2 and breast cancer.